Alefacept

DB00092ApprovedWithdrawnProtein Based TherapiesCD2-directed LFA-3/Fc Fusion Protein

Alefacept is a recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1.

Protein structure of Alefacept
Mechanism
Curator reviewed
Primary indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasisCurator reviewed
Formula / weight
C2306H3594N610O694S26 · 51801.1 Da
First approval
Canada, 2006 · United States, 2003
Code names
ASP0485 · BG-9273 · BG-9712 · LFA-3CD2 · LFA-3TIP

Resolves to

Compound
UNIIELK3V90G6CCAS222535-22-0ChEMBLCHEMBL1201571
Clinical / RWD
RxNorm299635ATCL04AA15PharmGKBPA164748040
Targets
P06729CD2P19256CD58P08637FCGR3AO75015FCGR3B

What you can answer from here — as of July 17, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
362Drug interactionsStructured to mechanism, not free text
Sign in
33Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
2Marketed productsAcross 2 countries and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 23 drug categories
Sign in
15+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Alefacept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In